Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kira Pharmaceuticals (Suzhou) Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a distinct art unit. The portfolio shows a focused prosecution effort with only one active matter under review. This allows the company to concentrate its efforts on overcoming the specific technical hurdles identified by the examiner in this case.
The busiest examiner for the company is KUCKLA, ANNA GRACE, who is responsible for 1 pending office action. This examiner handles the entire pending workload for the company. Practitioners should focus on the specific examination style of this examiner to navigate the current prosecution requirements effectively. Because the workload is limited to a distinct examiner and a distinct art unit, the company can develop a specialized strategy for this case. The outcome of this pending action will determine the company's immediate progress in securing patent protection for its biotechnology innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020242 | COMPOUNDS AS C5AR INHIBITORS | KUCKLA, ANNA GRACE | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18020242 | COMPOUNDS AS C5AR INHIBITORS | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 22d overdue | Pending | Feb 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial